BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29149426)

  • 1. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
    Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
    Yanagisawa N; Ichinoe M; Mikami T; Nakada N; Hana K; Koizumi W; Endou H; Okayasu I
    J Clin Pathol; 2012 Nov; 65(11):1019-23. PubMed ID: 22813728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.
    Kaira K; Sunose Y; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Segawa A; Furuya M; Mori M; Oyama T; Takeyoshi I
    Br J Cancer; 2012 Aug; 107(4):632-8. PubMed ID: 22805328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
    Kaira K; Sunose Y; Ohshima Y; Ishioka NS; Arakawa K; Ogawa T; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Itoh H; Nagamori S; Kanai Y; Yamaguchi A; Segawa A; Ide M; Mori M; Oyama T; Takeyoshi I
    BMC Cancer; 2013 Oct; 13():482. PubMed ID: 24131658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
    Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
    Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
    Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
    Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
    Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
    Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.
    Ma Y; Okuda S; Okanishi H; Xu M; Jin C; Endou H; Ohgaki R; Kanai Y
    J Pharmacol Sci; 2024 May; 155(1):14-20. PubMed ID: 38553134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Tanaka S; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Br J Cancer; 2008 Feb; 98(4):742-8. PubMed ID: 18253116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
    Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
    J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
    PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
    Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
    Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma.
    Sato K; Miyamoto M; Takano M; Furuya K; Tsuda H
    Virchows Arch; 2019 Jun; 474(6):701-710. PubMed ID: 30637450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.
    Toyoda M; Kaira K; Ohshima Y; Ishioka NS; Shino M; Sakakura K; Takayasu Y; Takahashi K; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Chikamatsu K
    Br J Cancer; 2014 May; 110(10):2506-13. PubMed ID: 24762957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
    Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
    Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
    Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.
    Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.